AVTR Stock Analysis: Avantor | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 10.308m USD | 12M Return: 9.5% | US05352A1007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 134M
EPS Trend: -88.3%
Qual. Beats: 1
Rev. Trend: -97.6%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 7.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Avantor, Inc. (NYSE: AVTR) is a U.S.-based supplier of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries, with operations across the Americas, Europe, Asia, the Middle East, and Africa. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania, and went public on the NYSE in May 2019.
The business operates across three core offerings: materials and consumables (including purity chemicals, reagents, lab supplies, single-use assemblies, chromatography resins, and clinical trial kits); equipment and instrumentation (such as filtration systems, incubators, analytical instruments, ultra-low-temperature freezers, and peristaltic pumps); and services and specialty procurement, which includes onsite lab and production support, sourcing, and biopharmaceutical material scale-up. It also provides scientific research support services like DNA extraction, bioreactor servicing, compound management, and cleanroom maintenance.
Avantor sits within the Life Sciences Tools & Services sub-industry of the Health Care sector, supplying inputs that are largely non-discretionary for its customers research and production workflows, which supports a recurring, project-based revenue profile tied to drug development, diagnostics, and broader lab activity.
- Biopharma revenue growth accelerates as biotech funding rebounds
- Operating margins under pressure from inflation and acquisition costs
- Leverage reduction remains key focus after recent acquisitions
| Net Income: -578.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.43 > 1.0 |
| NWC/Revenue: 16.46% < 20% (prev -0.92%; Δ 17.38% < -1%) |
| CFO/TA 0.05 > 3% & CFO 597.0m > Net Income -578.0m |
| Net Debt (3.39b) to EBITDA (125.3m): 27.06 < 3 |
| Current Ratio: 1.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (677.2m) vs 12m ago -0.67% < -2% |
| Gross Margin: 31.83% > 18% (prev 33.25%; Δ -1.42% > 0.5%) |
| Asset Turnover: 53.84% > 50% (prev 52.17%; Δ 1.67% > 0%) |
| Interest Coverage Ratio: -1.64 > 6 (EBIT TTM -293.1m / Interest Expense TTM 178.9m) |
| A: 0.09 (Total Current Assets 2.46b - Total Current Liabilities 1.38b) / Total Assets 11.6b |
| B: 0.15 (Retained Earnings 1.75b / Total Assets 11.6b) |
| C: -0.02 (EBIT TTM -293.1m / Avg Total Assets 12.2b) |
| D: 0.94 (Book Value of Equity 5.63b / Total Liabilities 5.97b) |
| Altman-Z'' = 1.93 = BBB |
| DSRI: 1.01 (Receivables 1.14b/1.15b, Revenue 6.56b/6.67b) |
| GMI: 1.04 (GM 33.25% / 31.83%) |
| AQI: 0.97 (AQ_t 0.72 / AQ_t-1 0.74) |
| SGI: 0.98 (Revenue 6.56b / 6.67b) |
| TATA: -0.10 (NI -578.0m - CFO 597.0m) / TA 11.6b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of October 07, 2026, the stock is trading at USD 15.43 with a total of 11,387,730 shares traded. Over the past week, the price has changed by +1.25%, over one month by +1.18%, over three months by +48.79% and over the past year by +9.51%.
Current recommended Stop Loss: 14.90 (which is 3.4% or 1.1 ATR below the current price).
Avantor has received a consensus analysts rating of 3.76. Therefore, it is recommended to hold AVTR.
- StrongBuy: 6
- Buy: 4
- Hold: 11
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.7 | -5% |
P/E Forward = 16.8634
P/S = 1.571
P/B = 1.7731
Revenue TTM = 6.56b USD
EBIT TTM = -293.1m USD
EBITDA TTM = 125.3m USD
Long Term Debt = 3.66b USD (from longTermDebt, last quarter)
Short Term Debt = 37.0m USD (from shortTermDebt, last quarter)
Debt = 3.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.39b USD (calculated: Debt 3.70b - CCE 306.8m)
Enterprise Value = 13.7b USD (10.3b + Debt 3.70b - CCE 306.8m)
Interest Coverage Ratio = -1.64 (Ebit TTM -293.1m / Interest Expense TTM 178.9m)
EV/FCF = 30.13x (Enterprise Value 13.7b / FCF TTM 454.7m)
FCF Yield = 3.32% (FCF TTM 454.7m / Enterprise Value 13.7b)
FCF Margin = 6.93% (FCF TTM 454.7m / Revenue TTM 6.56b)
Net Margin = -8.81% (Net Income TTM -578.0m / Revenue TTM 6.56b)
Gross Margin = 31.83% ((Revenue TTM 6.56b - Cost of Revenue TTM 4.47b) / Revenue TTM)
Gross Margin QoQ = 31.73% (prev 31.66%)
Tobins Q-Ratio = 1.18 (Enterprise Value 13.7b / Total Assets 11.6b)
Interest Expense / Debt = 4.84% (Interest Expense 178.9m / Debt 3.70b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -231.5m (EBIT -293.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.78 (Total Current Assets 2.46b / Total Current Liabilities 1.38b)
Debt / Equity = 0.66 (Debt 3.70b / totalStockholderEquity, last quarter 5.63b)
Debt / EBITDA = 27.06 (Net Debt 3.39b / EBITDA 125.3m)
Debt / FCF = 7.46 (Net Debt 3.39b / FCF TTM 454.7m)
Total Stockholder Equity = 5.59b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.74% (Net Income -578.0m / Total Assets 11.6b)
RoE = -10.34% (Net Income TTM -578.0m / Total Stockholder Equity 5.59b)
RoCE = -3.17% (EBIT -293.1m / Capital Employed (Equity 5.59b + L.T.Debt 3.66b))
RoIC = -2.33% (negative operating profit) (NOPAT -231.5m / Invested Capital 9.94b)
WACC = 5.94% (E(10.3b)/V(14.0b) * Re(6.70%) + D(3.70b)/V(14.0b) * Rd(4.84%) * (1-Tc(0.21)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.87 | Cagr: -0.27%
[DCF] Terminal Value 73.10% ; FCFF base≈495.2m ; Y1≈434.2m ; Y5≈350.8m
[DCF] Fair Price = 3.31 (EV 5.63b - Net Debt 3.39b = Equity 2.24b / Shares 676.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -88.32 | EPS CAGR: -8.48% | SUE: 1.89 | # QB: 1
Revenue Correlation: -97.62 | Revenue CAGR: -2.66% | SUE: 3.30 | # QB: 3
EPS current Quarter (2026-09-30): EPS=0.21 | Chg30d=+0.14% | Revisions=+58% | Analysts=17
EPS current Year (2026-12-31): EPS=0.81 | Chg30d=+0.09% | Revisions=+83% | GrowthEPS=-9.7% | GrowthRev=+0.6%
EPS next Year (2027-12-31): EPS=0.88 | Chg30d=-0.03% | Revisions=+82% | GrowthEPS=+8.4% | GrowthRev=+2.4%
[Analyst] Revisions Ratio: +88% (up=37, down=1)